Secondary craniofacial sarcomas following retinoblastoma: a systematic review.

Secondary craniofacial sarcomas following retinoblastoma: a systematic review.

World Neurosurg. 2017 Feb 15;:

Authors: Yamanaka R, Hayano A

Abstract
OBJECTIVE: We conducted the largest systematic review of individual patient data to characterize secondary craniofacial sarcomas following retinoblastoma.
METHODS: We conducted a systemic search of the PubMed databases, and compiled a comprehensive literature review. Student t-tests were used to evaluate differences between variables. Kaplan-Meier analysis was used to estimate survival. Statistical significance was assessed by using a log-rank test.
RESULTS: We analyzed 220 cases of secondary craniofacial sarcomas, including 112 osteosarcomas. The average age of onset for retinoblastoma was 1.20 ± 2.77 years. External-beam radiotherapy was delivered in 207 (94.0%) and chemotherapy in 53 (24.0%) patients.The latency period between retinoblastoma diagnosis and the onset of secondary sarcomas was 12.0 years. Cranial extension was found in 66 cases (30.0%). The median overall survival was worse with cranial extension (p=0.0073). In cranial extended patients, the median survival in patients who received chemotherapy was 41 months, whereas patients who did not receive chemotherapy had a median suival of 12 months (p =0.0020).
CONCLUSIONS: The risk of incidence of secondary sarcomas in retinoblastoma patients warrants longer follow-up periods. Moreover, chemotherapy should be considered as a potential treatment option for secondary cranial sarcomas following retinoblastoma.

PMID: 28214635 [PubMed - as supplied by publisher]

http://ift.tt/2kQtcIf